PATIENT-SPECIFIC GENE EDITING: LEGAL AUTHORIZATION, REGULATORY LIABILITY AND ETHICAL GOVERNANCE IN INDIA

1. INTRODUCTION

Patient-specific gene editing refers to the development and application of genetic interventions designed to address a particular patient's genetic condition, disease-causing mutation, or individual medical requirements. It may involve individualized gene-editing therapies, customized genetic treatment strategies, and therapeutic interventions developed for rare or otherwise difficult-to-treat genetic disorders.

These technologies offer significant opportunities for precision medicine, particularly for patients suffering from inherited disorders and serious genetic diseases. However, they also raise complex legal questions concerning patient consent, clinical-trial authorization, genetic privacy, safety assessment, medical negligence, research ethics, and long-term monitoring.

In India, there is no separate comprehensive statute exclusively governing patient-specific gene-editing authorization. Such interventions must be assessed under existing pharmaceutical, biotechnology, biomedical research, clinical-trial, and constitutional frameworks.

An important legal distinction exists between somatic gene editing, which targets cells of an individual patient, and germline gene editing, which may produce heritable genetic changes. Their ethical and regulatory implications are substantially different.

2. LEGAL FRAMEWORK GOVERNING PATIENT-SPECIFIC GENE EDITING

A. DRUGS AND COSMETICS ACT, 1940

The Act provides the principal statutory foundation for regulating drugs and pharmaceutical products in India.

Where an individualized gene-editing intervention qualifies as a new drug or regulated biological product, applicable manufacturing, clinical-trial, and marketing authorization requirements must be satisfied.

Relevant provisions include:

Section 3(b): Definition of drugs, including specified biological products.

Section 18: Restrictions concerning manufacture, sale, and distribution of drugs in violation of statutory requirements.

Section 27: Penalties for specified offences involving non-compliant drugs.

Section 33: Central Government rule-making powers.

B. NEW DRUGS AND CLINICAL TRIALS RULES, 2019

These Rules provide an important regulatory framework for clinical investigation and approval of new drugs.

Patient-specific gene-editing interventions may require regulatory authorization depending on their classification and intended use.

Relevant requirements include:

Appropriate permission for regulated clinical trials.

Approval from an appropriately constituted Ethics Committee.

Informed consent from the research participant.

Compliance with applicable safety-monitoring requirements.

Reporting of serious adverse events.

Compliance with applicable compensation requirements for clinical-trial-related injury or death.

The fact that a treatment is developed for only one patient does not automatically exempt it from applicable regulatory requirements.

C. DEPARTMENT OF BIOTECHNOLOGY GUIDELINES

The Department of Biotechnology's National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019 provide an important framework for gene-therapy development in India.

They address regulatory oversight, product development, preclinical evaluation, clinical investigation, ethical review, and safety considerations.

D. ICMR NATIONAL ETHICAL GUIDELINES, 2017

The Indian Council of Medical Research guidelines establish ethical standards for biomedical and health research involving human participants.

Important principles include:

Voluntary informed consent.

Protection of vulnerable participants.

Scientific validity.

Independent ethical review.

Confidentiality of genetic information.

Fair participant selection.

Protection against unnecessary research risks.

E. CONSTITUTION OF INDIA

Article 21 protects life, personal liberty, bodily autonomy, and privacy.

Article 14 requires non-arbitrary treatment in governmental authorization and healthcare decisions.

These constitutional protections are particularly important where experimental genetic interventions involve serious medical risks or sensitive personal information.3. AUTHORIZATION AND APPROVAL REQUIREMENTS

Patient-specific gene-editing treatment must undergo regulatory assessment according to its classification, clinical purpose, and method of administration.

A. CENTRAL DRUGS STANDARD CONTROL ORGANIZATION (CDSCO)

CDSCO is the principal central drug regulator responsible for relevant new-drug approvals and clinical-trial permissions.

The regulatory process may involve:

Determination of whether the proposed intervention qualifies as a regulated gene-therapy product or new drug.

Submission of the prescribed regulatory application.

Scientific and safety assessment by the competent regulatory authority.

Ethics Committee approval where human research is involved.

Clinical-trial authorization where required.

Appropriate manufacturing and quality-control permissions.

Monitoring and reporting of adverse events.

B. INSTITUTIONAL BIOSAFETY COMMITTEE (IBSC)

The IBSC provides institutional oversight of applicable biotechnology research activities and biosafety compliance.

C. REVIEW COMMITTEE ON GENETIC MANIPULATION (RCGM)

The RCGM operates under the Department of Biotechnology framework and provides oversight concerning relevant genetic engineering research and associated biosafety matters.

D. ETHICS COMMITTEE

An appropriately constituted Ethics Committee must independently evaluate relevant human-participant research.

Its responsibilities include reviewing informed consent, participant selection, risks, potential benefits, confidentiality, and safeguards for vulnerable patients.

E. REGULATORY DEVELOPMENTS IN 2026

The Central Government amended the Drugs Rules, 1945, on 2 July 2026, bringing gene-therapeutic products, cell or stem-cell-derived products, and xenografts within the expanded Centrally License Approving Authority framework.

This development strengthens centralized regulatory oversight of advanced therapies and is particularly relevant to patient-specific gene-therapy manufacturing and authorization.

Press Information Bureau+1

4. INFORMED CONSENT AND PATIENT RIGHTS

Informed consent is one of the most important legal requirements in individualized genetic treatment.

Before participation in an experimental gene-editing intervention, patients should receive appropriate information concerning:

The experimental or established status of the treatment.

Potential benefits and foreseeable risks.

Available alternative treatments.

Possibility of treatment failure.

Possible unintended biological consequences.

Long-term medical monitoring.

Confidentiality and future use of genetic information.

The right to withdraw from research, subject to applicable legal and practical limitations.

For minors or patients lacking decision-making capacity, applicable representative-consent and assent requirements must be followed.

Consent cannot independently legalize a treatment that lacks mandatory regulatory authorization.

5. SOMATIC AND GERMLINE GENE EDITING: LEGAL DISTINCTIONS

A. SOMATIC GENE EDITING

Somatic gene editing concerns genetic modifications in the treated individual's non-reproductive cells.

It may be considered for therapeutic research and treatment, subject to the applicable regulatory, clinical, ethical, and manufacturing requirements.

B. GERMLINE GENE EDITING

Germline interventions raise additional ethical and intergenerational concerns because genetic changes may be inherited by future generations.

India's regulatory framework treats human germline interventions with substantial restriction. The DBT draft regulatory framework on genome-edited organisms identifies human germline cells as restricted for human applications.

C. PATIENT-SPECIFIC EXEMPTION

There is no general legal exemption merely because a proposed genetic intervention is developed for one patient, concerns a rare disease, or is intended to save a patient's life.

Individualized treatment must still satisfy the applicable statutory requirements.

6. IMPORTANT JUDICIAL DECISIONS AND CASE LAWS

The following Supreme Court decisions establish important principles relevant to patient-specific gene editing. The first is a particularly important recent authority concerning experimental advanced therapies; the remaining decisions provide direct or analogous constitutional, consent, and medical-liability principles.

1. Yash Charitable Trust v. Union of India, 2026 INSC 96 — DIRECT ANALOGOUS AUTHORITY

The Supreme Court delivered its judgment on 30 January 2026 concerning the unauthorized promotion and administration of experimental stem-cell interventions for autism spectrum disorder.

The Court held that experimental stem-cell interventions could not be offered as routine clinical treatment outside an approved and monitored research or clinical-trial framework.

Legal principle: Patient consent does not authorize scientifically unvalidated or legally unauthorized medical interventions.

Relevance: This judgment is highly relevant to experimental patient-specific gene-editing therapies offered outside the applicable regulatory framework.

2. Samira Kohli v. Dr. Prabha Manchanda, (2008) 2 SCC 1 — DIRECT AUTHORITY

The Supreme Court established important principles concerning valid medical consent and patient autonomy.

It held that consent must be voluntary, informed, and based on adequate disclosure concerning the proposed treatment, its purpose, benefits, alternatives, and substantial risks.

Legal principle: A patient's consent to one medical procedure cannot automatically authorize a different procedure.

Relevance: Patients undergoing individualized gene-editing interventions must receive appropriate information and provide valid consent.

3. Justice K.S. Puttaswamy v. Union of India, (2017) 10 SCC 1 — DIRECT CONSTITUTIONAL AUTHORITY

The Supreme Court recognized privacy as a fundamental right under Article 21 and other constitutional freedoms.

Legal principle: Informational privacy, personal autonomy, and protection of sensitive personal information are constitutionally protected.

Relevance: Patient-specific genetic information must be protected against unauthorized disclosure, misuse, and disproportionate governmental or private access.

4. Selvi v. State of Karnataka, (2010) 7 SCC 263 — ANALOGOUS AUTHORITY

The Supreme Court examined constitutional restrictions on involuntary scientific investigative techniques, including their relationship with personal liberty and bodily autonomy.

Legal principle: Scientific techniques cannot be imposed without considering constitutional protections concerning individual autonomy and personal liberty.

Relevance: Compulsory genetic interventions or involuntary collection of biological material raise important constitutional questions.

5. Sharda v. Dharmpal, (2003) 4 SCC 493 — ANALOGOUS AUTHORITY

The Supreme Court examined the circumstances in which medical examinations may be ordered by courts and the balance between privacy and competing legal interests.

Legal principle: Medical intervention involving bodily privacy requires appropriate legal justification.

Relevance: Genetic examination and patient-specific interventions must respect bodily integrity and applicable consent requirements.

6. M.A. Biviji v. Sunita, 2023 INSC 938 — DIRECT ANALOGOUS MEDICAL LIABILITY AUTHORITY

The Supreme Court examined medical negligence and the standard of care expected from medical professionals.

Legal principle: Medical negligence must be assessed against the applicable standard of reasonable professional care and established medical practice.

Relevance: Doctors administering experimental gene-editing treatments without appropriate scientific justification, regulatory authorization, or professional safeguards may face negligence and disciplinary liability.

7. LIABILITY FOR UNAUTHORIZED GENE-EDITING INTERVENTIONS

Different participants may incur liability depending on their individual responsibilities.

A. MEDICAL PRACTITIONERS

Doctors may face professional disciplinary action, civil compensation claims, and, where criminal ingredients are established, criminal prosecution for unauthorized or negligent interventions.

B. RESEARCH INSTITUTIONS

Institutions may face regulatory action for conducting unauthorized clinical research, violating ethics requirements, or failing to protect research participants.

C. BIOTECHNOLOGY COMPANIES

Companies may incur liability for manufacturing non-compliant products, misrepresenting treatment effectiveness, violating intellectual-property rights, or supplying defective therapeutic products.

D. CLINICAL-TRIAL SPONSORS

Sponsors may face applicable obligations concerning participant safety, compensation, regulatory reporting, and compliance with approved research protocols.

E. DATA CONTROLLERS AND REPOSITORY ADMINISTRATORS

Organizations processing identifiable genetic information must comply with applicable data-protection requirements, including security safeguards and lawful processing obligations.

8. PENALTIES AND LEGAL CONSEQUENCES

Depending on the applicable statutory violation, consequences may include:

Suspension or cancellation of relevant manufacturing or clinical permissions.

Prohibition of unauthorized clinical trials.

Monetary penalties and criminal prosecution under applicable legislation.

Compensation for clinical-trial-related injuries where legally established.

Medical registration suspension or professional disciplinary proceedings.

Civil liability for negligence and defective treatment.

Restrictions on research funding and institutional activities.

Liability for unauthorized disclosure or misuse of genetic information.

9. REGULATORY GAPS AND FUTURE LEGAL REFORMS

India would benefit from a dedicated legal framework addressing:

Individualized gene-editing authorization.

Separate regulatory treatment of somatic and germline interventions.

Long-term monitoring and patient follow-up.

Independent review of exceptional single-patient interventions.

Compensation mechanisms for unforeseen treatment injuries.

Protection of genetic information and familial privacy.

Cross-border collaboration and transfer of genetic material.

Clear allocation of liability among doctors, manufacturers, sponsors, and research institutions.

10. CONCLUSION

Patient-specific gene editing has considerable potential to transform the treatment of rare genetic disorders and other serious diseases. Nevertheless, individualized medical treatment cannot operate outside the framework of patient safety, regulatory authorization, informed consent, and ethical research.

In India, the Drugs and Cosmetics Act, 1940, New Drugs and Clinical Trials Rules, 2019, National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019, and applicable constitutional and data-protection provisions form the principal regulatory foundation.

The Supreme Court's judgment in Yash Charitable Trust v. Union of India (2026) is particularly significant because it reinforces the distinction between experimental research and routine clinical treatment. Together with Samira Kohli, Puttaswamy, and M.A. Biviji, it provides important legal principles for protecting patients while supporting responsible development of individualized genetic medicine.